Literature DB >> 1280620

Properties of soluble CR2 in human serum.

N R Ling1, B Brown.   

Abstract

A soluble form of complement receptor number 2 (sCR2) found in human serum closely resembles that produced in culture by B lymphoblastoid cells. Epitope analysis with a panel of CD21 monoclonal antibodies revealed only minor differences between antigen from the two sources. Purified sCR2 from both sources bound to C3dg prepared from human or mouse serum and to u.v.-inactivated Epstein-Barr virus. SDS-PAGE analysis of culture supernates of B-lymphoid cells labelled by growth in medium containing 35S-methionine revealed a major component of molecular weight approximately 130 kDa and another band at 30 kDa. Incubation with endoglycosidase F reduced the size of the high molecular weight component. Gel filtration of untreated serum or culture supernate revealed that, in its native state, sCR2 behaved as a molecule or complex of apparent molecular weight 320 kDa. Possible explanations are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280620     DOI: 10.1016/S0171-2985(11)80656-X

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  4 in total

1.  Origin and properties of soluble CD21 (CR2) in human blood.

Authors:  N R Ling; D L Hardie; G D Johnson; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

2.  Soluble CD21 in sera and synovial fluid of arthritic patients.

Authors:  Thomas Grottenthaler; Johannes von Kempis; Sigune Goldacker; Harald Illges
Journal:  Rheumatol Int       Date:  2005-03-16       Impact factor: 2.631

3.  Pitfalls in the measurement of soluble forms of cell surface receptors.

Authors:  N R Ling
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

4.  Determination of soluble CD21 as a parameter of B cell activation.

Authors:  H P Huemer; C Larcher; W M Prodinger; A L Petzer; M Mitterer; N Falser
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.